Therapeutic targeting in the silent era: advances in non-viral siRNA delivery

Show simple item record

dc.contributor.author Guo, Jianfeng
dc.contributor.author Fisher, Karen A.
dc.contributor.author Darcy, Raphael
dc.contributor.author Cryan, John F.
dc.contributor.author O'Driscoll, Caitríona M.
dc.date.accessioned 2013-01-29T10:11:16Z
dc.date.available 2013-01-29T10:11:16Z
dc.date.copyright 2010
dc.date.issued 2010-04
dc.identifier.citation GUO, J., FISHER, K. A., DARCY, R., CRYAN, J. F. & O'DRISCOLL, C. 2010. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Molecular BioSystems, 6, 1143-1161. doi: 10.1039/c001050m en
dc.identifier.volume 6 en
dc.identifier.startpage 1143 en
dc.identifier.endpage 1161 en
dc.identifier.issn 1742-206X
dc.identifier.uri http://hdl.handle.net/10468/933
dc.identifier.doi 10.1039/c001050m
dc.description.abstract Gene silencing using RNA-interference, first described in mammalian systems almost a decade ago, is revolutionizing therapeutic target validation efforts both in vitro and in vivo. Moreover, the potential for using short interfering RNA (siRNA) as a therapy in its own right is also progressing at a significant pace. However, the widespread use of such approaches is contingent on having appropriate systems to achieve clinically appropriate, safe, and efficient delivery of siRNA. There are many physicochemical and biological barriers to such delivery, and a growing emphasis on the design and characterisation of non-viral technologies that will overcome these barriers and expedite targeted delivery. This review discusses the considerations and challenges associated with use of siRNA-based therapeutics, including stability and off-target effects. Speculation is made on the properties of an ideal delivery system and the non-viral delivery approaches used to date, both in vitro and in vivo, are classified and discussed. Moreover, the ability of cyclodextrin-based delivery vectors to fulfil many of the criteria of an ideal delivery construct is also elaborated. en
dc.description.sponsorship Science Foundation Ireland (Strategic Research Cluster (Irish Drug Delivery Network); Science Foundation Ireland (Centre for Science Engineering & Technology); Science Foundation Ireland (Research Frontiers Programmes); Irish Research Council for Science Engineering and Technology (Embark initiative) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Royal Society of Chemistry en
dc.relation.uri http://pubs.rsc.org/en/content/articlelanding/2010/mb/c001050m
dc.rights © 2010 Royal Society of Chemistry en
dc.subject siRNA-based therapeutics en
dc.subject Non-viral technologies en
dc.subject Cyclodextrin en
dc.subject.lcsh Gene silencing en
dc.subject.lcsh Drug delivery systems en
dc.title Therapeutic targeting in the silent era: advances in non-viral siRNA delivery en
dc.type Article (peer-reviewed) en
dc.internal.authorurl http://publish.ucc.ie/researchprofiles/C019/caitrionaodriscoll en
dc.internal.authorcontactother Caitriona O'Driscoll, School Of Pharmacy, University College Cork, Cork, Ireland. +353-21-490-3000 Email: caitriona.odriscoll@ucc.ie en
dc.internal.availability Full text available en
dc.date.updated 2013-01-17T10:53:32Z
dc.description.version Accepted Version en
dc.internal.rssid 16860360
dc.internal.pmid 20431817
dc.contributor.funder Science Foundation Ireland en
dc.contributor.funder Irish Research Council for Science Engineering and Technology en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Molecular Biosystems en
dc.internal.copyrightchecked No. CORA - ROMEO - Accepted version permitted 12 months after publication. en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress caitriona.odriscoll@ucc.ie en


Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement